Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis

Montagnon, Carmen M.; Tolkachjov, Stanislav N.; Murrell, Dédée F.; Camilleri, Michael; Lehman, Julia S.

doi:10.1016/j.jaad.2020.11.076

Cited by 33 publications

(56 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pemphigoid disorders are autoimmune bullous dermatoses with autoantibodies against structural components at the dermal-epidermal junction leading to subepidermal splitting which leads to blistering of the skin [1,6]. BP is the most common pemphigoid disorder with autoantibodies against dystonin (implicated autoantigen BP180), which are hemidesmosomal proteins involved in adhesion at the dermalepidermal junction [1,2]. It mostly affects elderly patients more than 60 years of age [7].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Chatterjee¹,

Rashid²,

Syed³

et al. 2022

Cureus

View full text Add to dashboard Cite

Pembrolizumab is an immune checkpoint inhibitor being increasingly used as immunotherapy for a multitude of cancers. With the increasing use of these agents, various immune-related adverse events are being recognized. Lichenoid reaction, pruritus, and eczema are well-established cutaneous side effects of pembrolizumab, but bullous pemphigoid (BP) is a rare side effect of the drug. It is difficult to establish this diagnosis because it needs a detailed history of the timeline of the evolution of symptoms and careful ruling out of other etiologies, especially other drugs. Here, we present the case of a 66-year-old male who developed BP after receiving pembrolizumab therapy for non-small-cell lung cancer. Discontinuation of pembrolizumab and the use of topical and systemic steroids led to the complete resolution of symptoms. Physicians should be aware of this potential complication and keep it on their differential diagnosis when treating patients on immune checkpoint inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Bullous pemphigoid (BP) is the most common pemphigoid disorder with autoantibodies against dystonin leading to dermal-epidermal lysis [1,2]. Several medications have been identified to precipitate BP.…”

Section: Introductionmentioning

confidence: 99%

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Chatterjee¹,

Rashid²,

Syed³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Pemphigus herpetiformis, LABD, epidermolysis bullosa acquisita (EBA), bullous systemic lupus erythematosus (BSLE), and pemphigoid gestationis can mimic annular BP. 3 …”

Section: Discussionmentioning

confidence: 99%

Annular bullous pemphigoid: A case report and review of literature

Arès

Lim

Jung

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Bullous pemphigoid is an autoimmune blistering disease that primarily affects the geriatric population. It often presents as urticarial erythematous plaques, which evolve into subepidermal blisters accompanied by pruritus. Although rare, clinical variants of bullous pemphigoid have been documented. We present a rare case of annular bullous pemphigoid in a 50-year-old male and offer a brief review of the literature. Only five other case reports, including three in adults, have described this unusual presentation, which can mimic other autoimmune blistering diseases, including linear IgA bullous dermatosis and pemphigus herpetiformis. Therefore, histopathology and immunologic studies were essential in properly diagnosing this patient. Our case supports that annular blistering lesions can be a clinical variant of bullous pemphigoid.

show abstract

“…Despite the rarity of the disease, the pathogenesis is well-established and is considered to be similar to that of bullous pemphigoid with autoantibodies (immunoglobulin G1 [IgG1] subclass) directed against bullous pemphigoid antigen 180 (BP180) [ 53 , 54 ]. BP180 is found both in the basement membrane zone of the skin and in placental tissue and fetal membranes.…”

Section: Pregnancy-specific Pruritic Diseasesmentioning

confidence: 99%

Pruritus in Pregnancy

et al. 2022

View full text Add to dashboard Cite

Pruritus in pregnancy is a common and burdensome symptom that may be a first sign of a pregnancy-specific pruritic disease (atopic eruption of pregnancy, polymorphic eruption of pregnancy, pemphigoid gestationis, and intrahepatic cholestasis in pregnancy) or a dermatosis coinciding with pregnancy by chance. Despite its high prevalence, pruritus is often underrated by physicians, and data regarding the safety profiles of drugs for pruritus are very limited. In this review, we illustrate the epidemiology, possible pathophysiology, clinical characteristics, and diagnostic workup of various pregnancy-related diseases and discuss antipruritic treatments. The prevalence of pruritus in pregnancy demonstrates the importance of symptom recognition and the need for an holistic approach, taking into account both the potential benefits for the patient and the potential risks to the fetus.

show abstract

Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis

Cited by 33 publications

References 137 publications

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Annular bullous pemphigoid: A case report and review of literature

Pruritus in Pregnancy

Contact Info

Product

Resources

About